HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Nov 19, 2025 · 29m

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00)

Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant breast cancer (3:59)

General overview of proteolysis-targeting chimeras (PROTACs); comparison of PROTAC estrogen receptor (ER) degraders and selective ER degraders (7:39)

Early-phase data with vepdegestrant monotherapy or in combination with CDK4/6 inhibitors in ER-positive…